Genclis SAS Releases First Data for Severidia(r) Molecular

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genclis SAS Releases First Data for Severidia(r) Molecular Diagnostic in Triple-Negative Breast Cancer

NANCY, France, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Genclis, a molecular diagnostic company in the fields of allergy and cancer, announced today the presentation of the first clinical data for its molecular diagnostic test Severidia® in non-metastatic triple-negative breast cancer patients in the context of the Personalized Diagnostics Today virtual conference organized by the American Association for Clinical Chemistry (AACC).

The poster is available on the Company's website ( www.genclis.com ).

These data are based on a robust retrospective study conducted on a sample of 52 patients from 10 different clinical centers and for which a genomic sequencing was performed through NGS technology. Twenty patients were used in a training set and 32 patients, with a similar profile, were used in blind replication. Data showed that Genclis' proprietary algorithms were able to predict individual patient cancer severity with greater than 90 % accuracy: i.e. 100% of patients classified in the "good outcome" subgroup (2/3 of patients in the replication set) were alive after 2,500 days.

"Triple-negative breast cancer is the most severe form of breast cancer, for which current treatment options are radiotherapy and conventional chemotherapy. Clinicians know that a majority of patients do not truly benefit from this standard of care. At this stage, there are no methods to identify patient with the less severe forms of TNBC, hence it is expected that many patients received treatment with serious side effects that may not be truly useful." said Stéphane Boissel, CEO of Genclis. He added: "This first presentation of data for Severidia® is a very important step for Genclis. The market for tumor prognostic biomarker is set for a rapid growth and, once these NGS data will have been validated in larger clinical trials, Genclis could position its solutions as a new prognostic standard for clinicians" .

"It is a very good day for Genclis since, 7 years after discovering and patenting the DNA/RNA transcription infidelity principle, we are able to present the first example of the clinical utility of the concept." said Dr. Bernard Bihain, CSO and Chairman of the Board of Genclis. He added: "Today, we are developing Severidia® test in triple-negative breast cancer as well as in a type of lung cancer. The first data warrants conducting additional clinical studies in these indications as well as the development of Severidia® in other cancers with the objective of reaching the highest level of evidence in each indication that we address".

An oral presentation of the TNBC results will take place at the 4 th Munich Biomarker Conference, November 25-26, 2014, Munich, Germany.

About triple-negative breast cancer ("TNBC"):

Breast cancer has a global incidence of 1.677.000 new cases per year, including 794.000 new cases in developed countries (source: Globocan), of which 233.000 new cases in the USA and 367.000 new cases in the European Union. Breast cancer is qualified as "triple-negative" when estrogen, progesterone and HER2, the main targets of modern breast cancer therapeutic agents, are not overexpressed in these cells.

This type of cancer account for 15 to 25% of all breast cancers (source: Medscape), or between 120.000 and 200.000 new cases per year in developed countries. It is considered as the most deadly breast cancer form, with more than 25% of deaths within 5 years of diagnostic. Chemotherapy is used in around 50% of TNBC cancer cases. TNBC tumors respond to chemotherapy. However, they are genetically unstable and thus resistance to chemotherapy treatment are developed in the first five years after chemotherapy. It is known that around 2/3 of TNBC are non-severe TNBC. However, without any proper tool to segment patients based on the severity of their cancer, most patients undergo chemotherapy. It is commonly known that costs of care for TNBC are 80% above average breast cancer costs.

About Genclis:

Genclis is a molecular diagnostic company in the fields of allergy and cancer. Started in 2004, the Company initiated the commercialization of its allergy molecular diagnostic tests in 2014.

In the field of cancer diagnostic, Genclis based its development on the concept of DNA/RNA divergences due to transcription infidelity, an original, proprietary disruptive science. This science has already led to encouraging results in the severity prognostic of triple negative breast cancer ("TNBC"), a severe form of breast cancer. Genclis intends to rapidly impose its solution, Severidia©, as a standard for oncologists to offer their patients alternative treatment and monitoring options. 

Based in Nancy and Paris, Genclis had 40 employees as of October 1, 2014. Please visit: www.genclis.com

Contacts:

Stéphane Boissel , CEO: +33.6.74.78.09.25 - sboissel@genclis.com

Bernard Bihain , Chairman and CSO: +33.6.33.02.90.88 - bbihain@genclis.com

ATCG Press: Judith Aziza, +33.6.70.07.77.51 / Marielle Bricman, +33.6.26.94.18.53 - presse@atcg-partners.com

Severidia first Data http://hugin.info/164309/R/1866794/655810.pdf

HUG#1866794

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 113

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 83

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 211

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 252

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 197

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 63

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 30

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 16

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 213

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 50

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading

Top 5 Most Recently Viewed Articles

RAMM Pharma Corp. Strategizes Potential Sale of Canapar

Updated Category News Views 184

RAMM Pharma Corp. Explores Strategic Sale Options RAMM Pharma Corp. (CSE: RAMM), along with its wholly owned subsidiaries, is considering the sale of its subsidiary, Canapar Corp., and its industrial facility situated in Italy. This strategy aligns with the Company’s goal of enhancing operational efficiency and focusing on growth avenues in the cannabinoid industry....

Continue Reading
Marquis Software Solutions Faces Major Data Breach Issues

Updated Category News Views 206

Marquis Software Solutions Faces Data Breach Concerns Recently, Marquis Software Solutions, a notable software and services provider, faced a serious incident regarding a data breach that may have compromised the personal information of many individuals. This breach raised significant concerns for anyone whose data might have been affected. Details of the Cybersecurity...

Continue Reading
Recovering Losses: GSK Securities Class Action Explained

Updated Category News Views 192

Understanding the GSK Securities Class Action Lawsuit Investors in GSK plc (NYSE: GSK) now find themselves presented with a significant opportunity to participate in a class action lawsuit. This legal action is initiated on behalf of purchasers of American Depositary Receipts (ADRs) from a defined Class Period. The relevant dates for this lawsuit span from early in 2020...

Continue Reading
CYPFER and Michael Bay Team Up for Cybersecurity Advancements

Updated Category News Views 366

Strengthening Cybersecurity in Entertainment with CYPFER In an era where digital security is paramount, CYPFER is leading the charge to develop comprehensive cybersecurity strategies tailored for the film and entertainment industry. The company has formed a partnership with iconic filmmaker Michael Bay, known for his blockbuster hits that captivate audiences worldwide....

Continue Reading
Chris Hall Appointed as CPO of IRIS Software Group

Updated Category News Views 108

Chris Hall Steps in as Chief Product Officer at IRIS Software Group Pivotal leadership appointment will accelerate product innovation and delivery of AI-first strategy IRIS Software Group, a renowned global provider of accounting, HR, payroll, and education software, has announced a significant enhancement to its leadership team with the appointment of Chris Hall as Chief...

Continue Reading